David Taber to Tacrolimus
This is a "connection" page, showing publications David Taber has written about Tacrolimus.
Connection Strength
7.046
-
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenet Genomics. 2023 04 01; 33(3):59-65.
Score: 0.753
-
Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit. 2021 06 01; 43(3):401-407.
Score: 0.668
-
A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant. 2020 08; 20(8):1969-1983.
Score: 0.626
-
Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial. Ann Pharmacother. 2020 12; 54(12):1185-1193.
Score: 0.625
-
Dosing Requirements of Extended-Release Tacrolimus (Astagraf XL) in African American Kidney Transplant Recipients Converted from Immediate-Release Tacrolimus (AAAKTRS). Ther Drug Monit. 2020 06; 42(3):415-420.
Score: 0.624
-
Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Clin Transplant. 2019 10; 33(10):e13679.
Score: 0.593
-
Change in Mycophenolate and Tacrolimus Exposure by Transplant Vintage and Race. Exp Clin Transplant. 2019 12; 17(6):707-713.
Score: 0.564
-
Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017 12; 101(12):2931-2938.
Score: 0.525
-
African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. Pharmacotherapy. 2015 Jun; 35(6):569-77.
Score: 0.440
-
Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver Transpl. 2002 Mar; 8(3):219-23.
Score: 0.176
-
Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSAFE Rx randomized controlled trial. Am J Health Syst Pharm. 2021 07 09; 78(14):1287-1293.
Score: 0.168
-
Safety and Efficacy of Perioperative Sublingual Tacrolimus in Pancreas Transplant Compared With Oral Tacrolimus. Exp Clin Transplant. 2021 06; 19(6):592-595.
Score: 0.166
-
Clinical Outcomes of Older Kidney Transplant Recipients. Am J Med Sci. 2021 08; 362(2):130-134.
Score: 0.164
-
Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplant Proc. 2000 May; 32(3):660-2.
Score: 0.155
-
Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. Clin Transplant. 2020 04; 34(4):e13844.
Score: 0.154
-
Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population. Clin Transplant. 2019 10; 33(10):e13701.
Score: 0.148
-
The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int. 2019 01; 32(1):84-94.
Score: 0.139
-
A Comparative Effectiveness Analysis of Early Steroid Withdrawal in Black Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017 01 06; 12(1):131-139.
Score: 0.123
-
Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clin Transplant. 2015 Mar; 29(3):222-6.
Score: 0.108
-
Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. Am J Nephrol. 2014; 40(1):19-28.
Score: 0.103
-
Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013 Dec; 15(6):551-8.
Score: 0.024